601 related articles for article (PubMed ID: 29175116)
1. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn PA; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Wakelee H; Thatcher N
J Thorac Oncol; 2018 Feb; 13(2):165-183. PubMed ID: 29175116
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Features of Advanced Squamous NSCLC.
Socinski MA; Obasaju C; Gandara D; Hirsch FR; Bonomi P; Bunn P; Kim ES; Langer CJ; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Spigel DR; Stinchcombe TE; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Sep; 11(9):1411-22. PubMed ID: 27296106
[TBL] [Abstract][Full Text] [Related]
3. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.
Langer CJ; Obasaju C; Bunn P; Bonomi P; Gandara D; Hirsch FR; Kim ES; Natale RB; Novello S; Paz-Ares L; Pérol M; Reck M; Ramalingam SS; Reynolds CH; Socinski MA; Spigel DR; Wakelee H; Mayo C; Thatcher N
J Thorac Oncol; 2016 Dec; 11(12):2066-2081. PubMed ID: 27575423
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
5. [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
Dong M; Li T; Chen J
Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):116-120. PubMed ID: 29526179
[TBL] [Abstract][Full Text] [Related]
6. Mouse models in squamous cell lung cancer: impact for drug discovery.
Singh AP; Adrianzen Herrera D; Zhang Y; Perez-Soler R; Cheng H
Expert Opin Drug Discov; 2018 Apr; 13(4):347-358. PubMed ID: 29394493
[TBL] [Abstract][Full Text] [Related]
7. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
Daaboul N; Nicholas G; Laurie SA
Curr Oncol; 2018 Jun; 25(Suppl 1):S77-S85. PubMed ID: 29910650
[TBL] [Abstract][Full Text] [Related]
8. Squamous non-small cell lung cancer as a distinct clinical entity.
Oliver TG; Patel J; Akerley W
Am J Clin Oncol; 2015 Apr; 38(2):220-6. PubMed ID: 25806712
[TBL] [Abstract][Full Text] [Related]
9. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis G; Ziogas DC; Kyriazoglou A; Lykka M; Koutsoukos K; Bamias A; Dimopoulos MA
Ann Transl Med; 2018 Apr; 6(8):143. PubMed ID: 29862232
[TBL] [Abstract][Full Text] [Related]
10. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
11. Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
Stinchcombe TE
Med Oncol; 2014 May; 31(5):960. PubMed ID: 24748366
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells.
Jeong EH; Lee TG; Ko YJ; Kim SY; Kim HR; Kim H; Kim CH
Cell Oncol (Dordr); 2018 Dec; 41(6):663-675. PubMed ID: 30178167
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Lim JS; Soo RA
Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
[TBL] [Abstract][Full Text] [Related]
15. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
16. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
[TBL] [Abstract][Full Text] [Related]
17. Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer.
Gemelli M; Bidoli P; Colonese F; Canova S; Cortinovis D
Front Biosci (Schol Ed); 2021 Dec; 13(2):190-201. PubMed ID: 34879471
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
Kuribayashi K; Funaguchi N; Nakano T
J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
[TBL] [Abstract][Full Text] [Related]
19. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
Rounds A; Kolesar J
Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]